Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport dose-ranging phase II study in continent women with idiopathic overactive bladder
2007-002999-34Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Oct 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum toxin type A in overactive bladder (OAB) (4 arms), sponsored by Ipsen. Primary endpoint: Percent change in cumulative urgency episodes at Week 12. Started Oct 2007; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2007-002999-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002999-34.